Millennium Management LLC reduced its holdings in Hill-Rom Holdings, Inc. (NYSE:HRC) by 19.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 751,249 shares of the medical technology company’s stock after selling 182,300 shares during the period. Millennium Management LLC owned approximately 1.14% of Hill-Rom worth $63,323,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. CAPROCK Group Inc. acquired a new position in Hill-Rom in the fourth quarter valued at approximately $211,000. DekaBank Deutsche Girozentrale increased its stake in Hill-Rom by 101.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock valued at $204,000 after purchasing an additional 1,367 shares in the last quarter. Braun Stacey Associates Inc. bought a new stake in Hill-Rom in the fourth quarter valued at approximately $233,000. BancorpSouth Bank bought a new stake in Hill-Rom in the fourth quarter valued at approximately $241,000. Finally, Atria Investments LLC bought a new stake in Hill-Rom in the fourth quarter valued at approximately $262,000. Institutional investors and hedge funds own 82.50% of the company’s stock.
Shares of Hill-Rom stock opened at $86.92 on Monday. The company has a current ratio of 1.75, a quick ratio of 1.29 and a debt-to-equity ratio of 1.39. Hill-Rom Holdings, Inc. has a 12-month low of $68.52 and a 12-month high of $91.11. The stock has a market cap of $5,751.82, a price-to-earnings ratio of 29.56, a PEG ratio of 1.40 and a beta of 1.03.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 23rd will be given a dividend of $0.20 per share. This is an increase from Hill-Rom’s previous quarterly dividend of $0.18. The ex-dividend date of this dividend is Thursday, March 22nd. This represents a $0.80 annualized dividend and a dividend yield of 0.92%. Hill-Rom’s dividend payout ratio is currently 24.49%.
Several brokerages have commented on HRC. Zacks Investment Research downgraded shares of Hill-Rom from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. ValuEngine raised shares of Hill-Rom from a “hold” rating to a “buy” rating in a research note on Friday, March 2nd. Needham & Company LLC reaffirmed a “buy” rating on shares of Hill-Rom in a research note on Friday, January 26th. KeyCorp reaffirmed a “buy” rating and issued a $97.00 target price on shares of Hill-Rom in a research note on Thursday, January 18th. Finally, Barclays reaffirmed a “buy” rating and issued a $100.00 target price on shares of Hill-Rom in a research note on Wednesday, January 10th. Five analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $95.38.
Hill-Rom Holdings, Inc is a global medical technology company. The Company partners with health care providers across care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency and respiratory health.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.